Thursday, January 25, 2024
WuXi Biologics (stock symbol: 2269.HK) has unveiled WuXiaADCC PLUSTM, an innovative mammalian cell line platform for developing and manufacturing afucosylated antibodies that enhance Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) response. ADCC plays a pivotal role in targeted antibody-based immunotherapy for cancer, and optimizing antibodies to boost ADCC response is essential for improving therapeutic effectiveness.
The WuXiaADCC PLUSTM platform addresses the increasing global demand for afucosylated antibodies by employing a highly efficient method—eliminating fucose from the N-glycosylation site. This modification enhances ADCC activity and increases the potency of antibody-based immunotherapies. Derived from WuXi Biologics' well-established WuXiaTM cell line, the WuXiaADCC PLUSTM is compatible with the WuXiaTM platform process, facilitating stable production of afucosylated antibodies at different scales for clinical and commercial manufacturing.
WuXi Biologics, expressed satisfaction with the launch of WuXiaADCC PLUSTM, providing a bioprocessing solution for global clients involved in developing novel antibody therapies. He emphasized WuXi Biologics' commitment to innovation, aiming to empower global partners in delivering high-quality and affordable biologics to patients worldwide.
The WuXiaTM Cell Line Development Platform, known for its high-yielding capabilities (up to approximately 11 g/L), is widely accepted by regulatory agencies globally. This platform has successfully generated over 800 cell lines expressing various biologics, including monoclonal and bispecific antibodies, fusion proteins, enzymes, and other recombinant proteins for clinical and commercial manufacturing.
Source: prnewswire.com
